0000000000076726

AUTHOR

Giammarco Mocci

showing 6 related works from this author

Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

2020

Abstract Background Few data exist regarding the long‐term effectiveness of golimumab in ulcerative colitis. No data have been reported on real‐world continuous clinical response. Objective This study aimed to describe the long‐term outcomes in a large cohort of patients on golimumab who had ulcerative colitis. Methods Consecutive patients with active ulcerative colitis, started on golimumab, were enrolled and prospectively followed up. The primary end point was to evaluate the long‐term persistence on golimumab therapy. Results A total of 173 patients with ulcerative colitis were studied. Of these, 79.2% were steroid dependent, and 46.3% were naïve to anti‐tumour necrosis factor alpha agen…

AdultMalemedicine.medical_specialtyAdolescentnaïveGolimumabPersistence (computer science)03 medical and health sciencesYoung Adult0302 clinical medicineremissionGastrointestinal AgentsInternal medicinemedicineHumansProspective StudiesAgedRetrospective Studiesulcerative colitisbusiness.industryTumor Necrosis Factor-alphaInflammatory Bowel DiseaseGastroenterologyAntibodies MonoclonalpersistenceMiddle Agedmedicine.diseaseUlcerative colitisGolimumabGolimumab; naïve; persistence; remission; ulcerative colitisOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyColitis UlcerativeFemaleOriginal Articlebusinessmedicine.drugFollow-Up StudiesIBD Ulcerative colitis Golimumab TNF-inhibitors
researchProduct

Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study

2019

Abstract Background Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results Seventy patients (64 Crohn’s disease…

MaleCrohn’s diseaseSettore MED/16 - REUMATOLOGIAPsoriaticCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Hepatology; GastroenterologyInflammatory bowel disease0302 clinical medicineClinical endpointCrohn's disease Psoriasis Psoriatic arthritis Ulcerative colitis UstekinumabCrohn's diseaseSettore MED/12 - GastroenterologiaGastroenterologyMiddle AgedUlcerative colitisCrohn's diseaseTreatment OutcomeItaly030220 oncology & carcinogenesisPsoriatic arthritis030211 gastroenterology & hepatologyFemaleUstekinumabmedicine.drugAdultmedicine.medical_specialty03 medical and health sciencesPsoriatic arthritisCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Adult; Aged; Arthritis Psoriatic; Dermatologic Agents; Female; Humans; Inflammatory Bowel Diseases; Italy; Logistic Models; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young AdultYoung AdultInternal medicinePsoriasisUstekinumabmedicineHumansPsoriasisAgedRetrospective StudiesHepatologybusiness.industryArthritisArthritis Psoriaticmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesCrohn’s disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; UstekinumabLogistic ModelsUlcerative colitisConcomitantDermatologic Agentsbusiness
researchProduct

Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey

2020

Telemedicinemedicine.medical_specialtytelemedicine; COVID-19; inflammatory bowel disease; Aftercare; Betacoronavirus; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicinePneumonia ViralAftercareInflammatory bowel diseaselaw.inventionSettore MED/12Betacoronaviruslawinflammatory bowel diseaseSurveys and QuestionnairesmedicineInfection controlImmunology and AllergyHumansMass ScreeningViralLetters to the EditorPandemicsMass screeningAcademicSubjects/MED00260Remote ConsultationCOVID-19; inflammatory bowel disease; telemedicine; Aftercare; Betacoronavirus; COVID-19; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; SARS-CoV-2; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicineInfection Controlbusiness.industrySARS-CoV-2Remote ConsultationGastroenterologyCOVID-19PneumoniaBiological productmedicine.diseaseInflammatory Bowel DiseasesIntensive care unitOrganizational InnovationTelemedicineHospitalizationDiarrheaItalyEmergency medicinemedicine.symptomtelemedicine; COVID-19; inflammatory bowel diseasebusinessCoronavirus InfectionsHospital UnitsInflammatory Bowel Diseases
researchProduct

Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammator…

2019

BACKGROUND Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined. METHODS In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis. RESULTS A total of 631 patients (late-onset 153, adult-onset 161, young adult-onset 317) were included. Colonic disease was more frequent in late-onset (P < 0005), stenosing behaviour was more frequent than in adult-onset (P < 0003), but fistulising disease was uncommon. Surgery rates were not different between the three age groups. Syste…

MaleDiseaseConstriction PathologictumoursInflammatory bowel diseaseLate Onset DisordersCohort Studiessurgery0302 clinical medicineCrohn DiseaseLate Onset DisordersMedicineYoung adultDigestive System Surgical ProceduresCrohn's diseaseGastroenterologyIleitisMiddle AgedColitisItaly030220 oncology & carcinogenesisoutcome030211 gastroenterology & hepatologyFemaleColorectal NeoplasmsCohort studysteroidsAdultmedicine.medical_specialtyAdolescentcomorbiditieselderly03 medical and health sciencesYoung AdultInternal medicineIntestinal FistulaHumansImmunologic FactorsGlucocorticoidsAgedRetrospective StudiesPolypharmacyHepatologybusiness.industrythiopurinesRetrospective cohort studymedicine.diseasecomorbidities; elderly; outcome; steroids; surgery; thiopurines; tumoursPolypharmacyTumor Necrosis Factor Inhibitorsbusiness
researchProduct

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct

P463 COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey…

2021

Abstract Background Vaccine hesitancy, the delay in acceptance or refusal of vaccination despite its availability, represents a threat to the diffusion and lethality of infectious diseases. COVID-19 vaccination has been recommended by national and international organizations in patients with Inflammatory Bowel Diseases (IBD). The aim of the study was to evaluate COVID-19 vaccine willingness and hesitancy in a population of Italian patients with IBD, and their determinants. Methods In February 2021 an online questionnaire focused on COVID-19 vaccine was proposed to a representative sample of Italian IBD patients. Socio-demographic characteristics, IBD features, lifestyle, perception of COVID…

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryGastroenterologyInflammatory Bowel DiseasesGeneral MedicineClinical: Therapy and Observationmedicine.diseaseInflammatory bowel diseasePoster presentationsVaccinationVaccination RefusalFamily medicineMedicineIn patientAdverse effectbusinessAcademicSubjects/MED00260Journal of Crohn's & Colitis
researchProduct